Clinicopathological Features of Telbivudine-Associated Myopathy
暂无分享,去创建一个
[1] M. Kumar,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.
[2] H. Lv,et al. Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion , 2014, Journal of Clinical Pathology.
[3] Janudin Baharin,et al. Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia , 2014, Electronic physician.
[4] M. Yuen,et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment , 2014, Journal of gastroenterology and hepatology.
[5] S. Luo,et al. Lactic acidosis during telbivudine treatment for HBV: a case report and literature review. , 2013, World journal of gastroenterology.
[6] B. J. Kim,et al. Dysphagia could be the first presenting symptom of telbivudine‐induced myopathy , 2013, Internal medicine journal.
[7] Eun Hye Kim,et al. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B , 2013, Clinical and molecular hepatology.
[8] F. Heppner,et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. , 2012, The American journal of pathology.
[9] J. Jia,et al. Telbivudine myopathy in a patient with chronic hepatitis B , 2012, International Journal of Clinical Pharmacy.
[10] X. Zou,et al. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine , 2011, Journal of viral hepatitis.
[11] M. Yuen,et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. , 2011, The Journal of antimicrobial chemotherapy.
[12] J. Finsterer,et al. Myotoxicity of telbivudine in pre-existing muscle damage , 2010, Virology Journal.
[13] A. Lok,et al. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. , 2009, Journal of hepatology.
[14] Dong Kuck Lee,et al. Long‐term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA , 2009, Hepatology.
[15] M. Manns,et al. Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .
[16] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[17] H. Kumada,et al. [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.
[18] R. Schinazi,et al. Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection , 2001, Antimicrobial Agents and Chemotherapy.
[19] R. Ike,et al. Muscle biopsy , 1995, Current opinion in rheumatology.
[20] J. Müller‐Höcker. Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: An age-related alteration , 1990, Journal of the Neurological Sciences.
[21] M. Dalakas,et al. Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.
[22] C. Franzini-armstrong,et al. Myology: Basic and clinical , 1986 .
[23] Itabashi Hh,et al. The muscle biopsy. , 1968 .